These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 18201149)
1. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections. Van Bambeke F; Harms JM; Van Laethem Y; Tulkens PM Expert Opin Pharmacother; 2008 Feb; 9(2):267-83. PubMed ID: 18201149 [TBL] [Abstract][Full Text] [Related]
2. The ketolides: a critical review. Zhanel GG; Walters M; Noreddin A; Vercaigne LM; Wierzbowski A; Embil JM; Gin AS; Douthwaite S; Hoban DJ Drugs; 2002; 62(12):1771-804. PubMed ID: 12149046 [TBL] [Abstract][Full Text] [Related]
3. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections. Hammerschlag MR; Sharma R Expert Opin Investig Drugs; 2008 Mar; 17(3):387-400. PubMed ID: 18321237 [TBL] [Abstract][Full Text] [Related]
4. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae. Zhanel GG; Hisanaga T; Nichol K; Wierzbowski A; Hoban DJ Expert Opin Emerg Drugs; 2003 Nov; 8(2):297-321. PubMed ID: 14661991 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of ketolides in the treatment of respiratory tract infections. Reinert RR J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934 [TBL] [Abstract][Full Text] [Related]
7. Will resistance to ketolides develop in Streptococcus pneumoniae? Leclercq R J Infect; 2002 Feb; 44 Suppl A():11-6. PubMed ID: 12150490 [TBL] [Abstract][Full Text] [Related]
8. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin. Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763 [TBL] [Abstract][Full Text] [Related]
9. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections? Carter PL Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591 [TBL] [Abstract][Full Text] [Related]
10. The wobbly status of ketolides: where do we stand? Georgopapadakou NH Expert Opin Investig Drugs; 2014 Oct; 23(10):1313-9. PubMed ID: 25154307 [TBL] [Abstract][Full Text] [Related]
11. Review of macrolides and ketolides: focus on respiratory tract infections. Zhanel GG; Dueck M; Hoban DJ; Vercaigne LM; Embil JM; Gin AS; Karlowsky JA Drugs; 2001; 61(4):443-98. PubMed ID: 11324679 [TBL] [Abstract][Full Text] [Related]
12. Telithromycin: a brief review of a new ketolide antibiotic. Scheinfeld N J Drugs Dermatol; 2004; 3(4):409-13. PubMed ID: 15303785 [TBL] [Abstract][Full Text] [Related]
13. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections. Lorenz J Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892 [TBL] [Abstract][Full Text] [Related]
15. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections. Lonks JR; Goldmann DA Clin Infect Dis; 2005 Jun; 40(11):1657-64. PubMed ID: 15889365 [TBL] [Abstract][Full Text] [Related]
16. Telithromycin: the first of the ketolides. Shain CS; Amsden GW Ann Pharmacother; 2002 Mar; 36(3):452-64. PubMed ID: 11895060 [TBL] [Abstract][Full Text] [Related]
17. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin. Felmingham D J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493 [TBL] [Abstract][Full Text] [Related]